Skip Navigation


JAC Advance Access originally published online on July 4, 2005
Journal of Antimicrobial Chemotherapy 2005 56(2):380-387; doi:10.1093/jac/dki235
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/2/380    most recent
dki235v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Winston, A.
Right arrow Articles by Emery, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winston, A.
Right arrow Articles by Emery, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy

Alan Winston1,2,*, Mark Bloch3, Andrew Carr2, Janaki Amin1, Patrick W. G. Mallon1,2, John Ray2, Debbie Marriott2, David A. Cooper1,2 and Sean Emery1

1 National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, 2010, Australia; 2 HIV, Immunology and Infectious Diseases Clinical Services Unit, St. Vincent's Hospital, Sydney, 2010, Australia; 3 Holdsworth House Medical Practice, Sydney, 2010, Australia

Received 5 April 2005; returned 9 May 2005; revised 13 May 2005; accepted 5 June 2005

* Correspondence address. 1st Floor St. Stephens Center, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK. Tel: +44-208-846-6508; Fax: +44-208-746-5628; E-mail: alan_winston71{at}yahoo.co.uk

Objectives: Atazanavir is a recently approved HIV protease inhibitor (PI). As with other PIs, careful attention to potential pharmacokinetic drug interactions in clinical practice is necessary. The aim of this study was to assess the clinical associations with plasma atazanavir concentrations in HIV-positive individuals.

Methods: Individuals established on an atazanavir-containing regimen, completed an interviewer-administered questionnaire recording atazanavir dosing characteristics, concomitant medication use and adherence. After completion, plasma atazanavir concentrations were measured.

Results: Of 100 individuals, mean trough plasma atazanavir concentrations (µg/L) were 282 (95% CI 95–468, n = 19) and 774 (95% CI 646–902, n = 81) in those on non- and ritonavir-boosted atazanavir regimens, respectively. Eighty-five individuals had HIV RNA <50 copies/mL. Seven individuals had atazanavir plasma concentrations below the assay limit of detection (<50 µg/L), all of whom had undetectable plasma HIV RNA. In a multivariate analysis, nevirapine use was associated with significantly lower trough atazanavir concentrations (P = 0.011) and lopinavir/ritonavir use with higher trough atazanavir concentrations (P = 0.032). Dosing characteristics (including food taken), concomitant medications (including drugs used for dyspepsia) and HIV RNA were not significantly associated with trough atazanavir concentrations.

Conclusions: In this cohort, despite the wide inter-individual variability of atazanavir trough concentrations, no significant association with dosing characteristics, concomitant medication (with the exception of nevirapine and lopinavir/ritonavir) or virological response was observed. Further work is needed to assess the optimal dosing regimen when using atazanavir with nevirapine.

Keywords: HAART , protease inhibitors , pharmacokinetics , drug interactions


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
R. M. M. Cleijsen, M. E. van de Ende, F. P. Kroon, F. V. Lunel, P. P. Koopmans, L. Gras, F. de Wolf, and D. M. Burger
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice
J. Antimicrob. Chemother., October 1, 2007; 60(4): 897 - 900.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
S. Staszewski, E. Babacan, C. Stephan, A. Haberl, A. Carlebach, P. Gute, S. Klauke, Y. Hermschulte, M. Stuermer, B. Dauer, et al.
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy
J. Antimicrob. Chemother., November 1, 2006; 58(5): 1024 - 1030.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Colombo, T. Buclin, M. Cavassini, L. A. Decosterd, A. Telenti, J. Biollaz, and C. Csajka
Population Pharmacokinetics of Atazanavir in Patients with Human Immunodeficiency Virus Infection
Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3801 - 3808.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
J Stebbing, M Bower, P Holmes, B Gazzard, and M Nelson
A single centre cohort experience with a new once daily antiretroviral drug.
Postgrad. Med. J., May 1, 2006; 82(967): 343 - 346.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.